New York, NY, Point Roberts, WA - December 17, 2013
(Investorideas.com newswire) Investorideas.com, an investor news and
research portal issues an exclusive sector snapshot on the rapidly
growing exosome market and opportunities with key insight from Enal
Razvi, Ph.D, Biotechnology Analyst and Managing Director of SelectBio
U.S.
For investors unfamiliar with exosomes, they are cell-derived
vesicles that are present in most biological fluids including blood and
urine, as well as other body fluids. Because the fluids are easily
accessible, they can be used as markers for disease progression.
Exosomes are described as tiny, nano-scale bubbles that are released
from cells capable of intercellular communication.
"Only five years ago the principals of communicating within the
body were hormones, immunology or neurology and now we have found
another way of communicating and sending genetic signals between cells,”
Life Technologies Corp (LIFE).
So why is something so small creating such a huge buzz? Two key
significant areas of growth in the sector are diagnostics and
therapeutics for diseases such as cancer.
According to a report earlier this year from Select Biosciences,
"Exosome research is growing exponentially as researchers from several
disparate disciplines are exploring the role of exosomes in
inter-cellular communication, immunological responses, stem cell
behavior, cancer cell communication, etc. Indeed, the potential of
exosomes and other classes of microvesicles as a means of molecular
cargo transport is being intensively studied. "
Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of
SelectBio U.S, one of a few experts covering the space, shared insight
with Investorideas.com in a recent conversation.
When we asked Enal to discuss what publicly traded companies are in
this new sector for investors, he said there are only a few to watch
including Life Technologies Corp (
LIFE) (currently being acquired by Thermo Fisher Scientific), Eli Lilly (
LLY) (due to their partnership with Exosome Diagnostics) and Aethlon Medical (
AEMD).
He went on to say, "Investors need to be aware of changes exosomes
allow, making companion diagnostics a reality. Exosomes can create a
paradigm shift for companion diagnostics based on circulating
biomarkers.
"Five years from now, or sooner, exosomes will become a key
diagnostic tool for cancers. If we don’t know the origin of tumors;
biomarkers can narrow down the source.
Why investors should pay attention to the space is because exosomes
can significantly reduce the cost and increase the compliance,
primarily for cancer, and make biopsies for personal medicine
longitudinal sense. It becomes a very invasive process for a patient to
get ongoing biopsies, so this new method of using exosomes for
diagnostics is very exciting for patients.
Currently the research market for exosomes is about $50 million but
this does not account for the opportunities in the diagnostics space
which will drive market growth and value creation.”
Aethlon Medical (
OTCBB: AEMD)
is one of the only companies that may be able to participate in both
diagnostics and therapeutics in the exosome space. The company recently
announced the launch of Exosome Sciences (ESI) as a subsidiary that is
advancing exosome-based strategies to diagnose and monitor the
progression of cancer, infectious disease and other life-threatening
conditions. Aethlon also attracted two of the best-known thought leaders
in the exosome industry to play key roles in the new company.
"We are well positioned to benefit from the exosome revolution,”
stated Aethlon Medical Chairman and CEO, Jim Joyce. "We are advancing
patented first-in-class therapeutic technology to eliminate the presence
of tumor-secreted exosomes that trigger the death of immune cells
necessary for combating cancer. On the diagnostic front, our Exosome
Sciences research team pioneered the field of exosome biology and is
actively advancing a pipeline of next generation diagnostic tools".
In September of this year, Exosome Diagnostics announced that it
entered into a collaboration agreement with Eli Lilly & Co.
(NYSE:LLY). "Exosome Diagnostics technology may provide a unique
opportunity to gain insight into the biology of complex conditions such
as cancer and immune disorders”, stated Andrew Schade, Senior Medical
Director, Diagnostic and Experimental Pathology at Eli Lilly. He further
stated that "Exosome technology enables biofluid molecular sampling and
the ability to monitor disease progression in real time. As Lilly
explores new ways to pursue patient tailoring, we'll continue to work
with partners to expand our capabilities."
Another company in the space, stem cell therapy development company ReNeuron (LON: RENE)
reported in early December, "We have highlighted a number of key
developments in the period, notably the successful and
earlier-than-planned development of a second-generation cryopreserved
CTX drug product for our stroke and critical limb ischaemia programmes,
our planned world-class cell manufacturing facility in South Wales, the
granting of Orphan Drug Designation for our retinitis pigmentosa
programme and the accelerated development of our CTX cell-based exosomes
therapeutic platform”.
Life Technologies Corp (LIFE) has created a mini documentary series
entitled 'Exosomes-The Next Small Thing’. "Exosomes are a very powerful
way, a new way of how cells communicate long distance… They are
powerful mediators that carry all the signaling and machinery necessary
to change the behavior of the neighboring cells".
http://www.lifetechnologies.com/ca/en/home/life-science/cell-analysis/exosomes/exosomes-documentary-episode-1.html
PDF for Exosomes Market Snapshot: Enal Razvi, Ph.D.
http://www.genengnews.com/media/pdf/GEN-Biomarket-Trends-Report-Exosomes%20Market-Landscape-2013.pdf
Bio for Enal Razvi, Ph.D- Biotechnology Analyst and Managing Director of SelectBio U.S
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology
and subsequent to receiving his Ph.D. went on to the Rockefeller
University in New York to serve as Aaron Diamond Post-doctoral fellow
under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his
discovery of dendritic cells in the early-70s with Zanvil Cohn].
Subsequently, Dr. Razvi completed his research fellowship at Harvard
Medical School. For the last two decades Dr. Razvi has worked with small
and large companies and consulted for more than 100 clients worldwide.
He currently serves as Biotechnology Analyst and Managing Director of
SelectBio U.S. He can be reached at
enal@selectbio.us
About Aethlon Medical, Inc. (AEMD)
Aethlon Medical creates innovative medical devices to address
life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like
Affinity Platform Technology) establishes the basis for a new class of
therapeutics that target the rapid elimination of disease enabling
particles from the circulatory system of treated patients. The lead
Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a
broad-spectrum of viral pathogens as well as tumor-secreted exosomes
that suppress the immune system of cancer patients. Aethlon is also
operating under two government contracts with the Defense Advanced
Research Projects Agency (DARPA) related the development of a medical
device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a
majority owned Aethlon subsidiary that is advancing exosome-based
strategies to diagnose and monitor cancer and infectious disease
progression. Additional information can be found at
www.AethlonMedical.com
News source:
http://www.hispanicbusiness.com/2013/12/4/reports_from_dalian_medical_university_advance.htm
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following
leading business sectors including biotech, tech, mining, mobile,
energy, water, defense renewable energy and Latin American stocks.
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at
http://www.linkedin.com/today/investorideas.com
Sign up for news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third
party publisher of news and research as well as creates original content
as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas
is a news source on Google news and Linkedintoday plus hundreds of
syndication partners. Our site does not make recommendations for
purchases or sale of stocks or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or
securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies,
news submissions, content marketing and online advertising. Contact each
company directly for press release questions. Disclosure is posted on
each release if required but otherwise the news was not compensated for
and is published for the sole interest of our readers. More disclaimer
info:
http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD compensates Investorideas three thousand per month for news and content publication and distribution
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere
to regulations of each country.
800-665-0411 - Source -
www.Investorideas.com